Wanda DePinto

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), A Potent and Selective Cyclin-Dependent Kinase Inhibitor with Significant in Vivo Antitumor Activity

Xin‐Jie Chu, Wanda DePinto, David Bartkovitz et al. · Journal of Medicinal Chemistry · 2006 · 116 citations · Full text

Drug Target, Pharmacotherapy, Cell Cycle +17

<i>In vitro</i> and <i>in vivo</i> activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

Wanda DePinto, Xin‐Jie Chu, Xuefeng Yin et al. · Molecular Cancer Therapeutics · 2006 · 102 citations · Full text

Molecular Pharmacology, Tumor Biology, Cell Cycle Block +15

A new series of potent oxindole inhibitors of CDK2

Kin‐Chun Luk, Mary Ellen Simcox, Andy Schutt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 51 citations · Full text

Medicinal Chemistry, Medicine, Mechanism Of Action +6

Synthesis of Potent Oxindole CDK2 Inhibitors

Apos Dermatakis, Kin‐Chun Luk, Wanda DePinto · Bioorganic & Medicinal Chemistry · 2003 · 48 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Medicine +3

Inhibition of S/G2 Phase CDK4 Reduces Mitotic Fidelity

Andrew Burgess, Matthew Wigan, Nichole Giles et al. · Journal of Biological Chemistry · 2006 · 31 citations · Full text

Cdk4-cyclin D, Signal Transduction, Cell Regulation +12